Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Real-time Estimate Cboe BZX
Other stock markets
 11:01:10 2024-04-30 am EDT 		5-day change 1st Jan Change
1.59 USD +0.63% Intraday chart for Corvus Pharmaceuticals, Inc. +2.94% -10.51%
Apr. 09 Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CI
Mar. 20 Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CI
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2
MT
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
CI
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation
DJ
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
CI
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma
CI
Corvus Completes FDA Meeting on Plans to Launch Phase 3 Cancer Trial; Shares Jump After-Hours
MT
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
CI
Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma
CI
CORVUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Corvus Pharmaceuticals, Inc. Presents New CPI-818 Data Demonstrating the Potential of Itk Inhibition as A Treatment for Solid and Hematologic Cancers
CI
Corvus Pharmaceuticals, Inc. Announces CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
CI
CORVUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. News Corvus Pharmaceuticals, Inc.
  5. Highlights